Caribou Biosciences (CRBU)
NASDAQ:CRBU
CRBU Stock Chart & Stats
$1.78
-$0.16(-8.56%)
At close: 4:00 PM EST
$1.78
-$0.16(-8.56%)
Day’s Range― - ―
52-Week Range$0.66 - $3.54
Previous CloseN/A
Volume598.80K
Average Volume (3M)1.20M
Market Cap
$172.01M
Enterprise Value$186.88M
Total Cash (Recent Filing)$139.34M
Total Debt (Recent Filing)$27.23M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
May 12, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding96,637,200
10 Day Avg. Volume1,354,975
30 Day Avg. Volume1,199,069
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.22
Price to Sales (P/S)13.31
P/FCF Ratio-1.32
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue16.75
Enterprise Value/Gross Profit18.98
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$8.75Price Target Upside391.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.34
Revenue Forecast (FY)$21.44M
Bulls Say, Bears Say
Bulls Say
Clinical ProfileClinical data for the lead allogeneic CAR-T candidate showed response rates and durability comparable to approved autologous therapies with lower rates of severe neurotoxicity, indicating a potentially competitive safety-efficacy profile.
Enrollment StrategyCRBU's plan to enroll patients regardless of prior BCMA exposure into the CB-011 dose expansion broadens the eligible patient pool and may accelerate enrollment and data readouts.
Regulatory EngagementEngagement with the U.S. Food and Drug Administration on pivotal trial design for vispa-cel in second-line large B-cell lymphoma could streamline the approval pathway and reduce late-stage development risk.
Bears Say
Dilution RiskThe need to raise additional capital increases the likelihood of shareholder dilution or accepting unfavorable financing terms if market conditions are weak.
Financing ShortfallAvailable cash is expected to fund some operations and start-up activities but additional capital will be required to fully fund the pivotal trial, creating execution risk until financing is secured.
Trial Timing RiskRequirement for extra funding may delay initiation or completion of the pivotal trial and push back key regulatory milestones if financing is not obtained in time.
Caribou Biosciences News
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $0.66 and its highest was $3.54 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $172.01M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is May 12, 2026 which is in 44 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on Mar 05, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.03.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate is -0.31.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 96,637,200 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went up 6.433%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Currently, no hedge funds are holding shares in CRBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caribou Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (391.57% Upside)
$8.75 (391.57% Upside)
Hedge Fund Trend
Decreased
By 21.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $18.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 11.7%
Last 30 Days ▲ 11.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.00%
12-Months-Change
Fundamentals
Return on Equity
-74.28%
Trailing 12-Months
Asset Growth
-40.77%
Trailing 12-Months
Company Description
Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
CRBU Stock 12 Month Forecast
Average Price Target
$8.75
▲(391.57% Upside)
Technical Analysis
Sangamo Biosciences
―
Cellectis SA
―
Cabaletta Bio
―
Elicio Therapeutics
―
Vor Biopharma
―
Ownership Overview
4.78% Insiders
6.17% Mutual Funds
12.73% Other Institutional Investors
68.83% Public Companies and
Individual Investors